pegvisomant (Somavert)

Introduction

Tradename: Somavert (FDA approved 2003)

Indications

• acromegaly

Dosage

daily subcutaneous injections

Mechanism of action

• growth hormone receptor antagonist
• normalizes growth IGF-1 levels in 90% of patients with acromegaly
• no effect on growth hormone secreting tumors

More general terms

• endocrine agent